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Abstract 
Progranulin (PGRN) is a cysteine rich secreted protein, expressed in epithelial cells, immune cells, neurons, and 
adipocytes. It was first identified for its growth factor-like properties, being involved in early embryogenesis and 
tissue remodeling, acting as an anti-inflammatory molecule. In the central nervous system, PGRN has neurotrophic 
and neuroprotective actions. There is also evidence of PGRN effects on cancer, contributing to tumor proliferation, 
invasion and cell survival. Recently, PGRN was recognized as an adipokine related to obesity and insulin resistance, 
revealing its metabolic function and pro-inflammatory properties. In obesity and type 2 diabetes mellitus, PGRN levels 
are increased. In renal disease, there is a relevant association, however, it is not known if it could contribute to kidney 
damage or if it is only a route of PGRN elimination. PGRN is an emerging molecule which demands studies in different 
fields. Possibly, it plays distinct functions in different tissues/cells and metabolic conditions. Here, we discuss potential 
mechanisms and recent data of PGRN pro-inflammatory actions, regarding obesity, insulin resistance, type 2 diabetes 
mellitus and kidney disease.
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Background
Progranulin (PGRN) is a 68–88  kDa cysteine rich 
secreted protein, also known as granulin-epithelin pre-
cursor, proepithelin or PC-cell derived growth factor [1, 
2]. It is encoded by GRN (PGRN gene) and expressed 
in many cell types, including epithelial cells, immune 
cells, neurons, and adipocytes [3]. In kidneys, PGRN 
is expressed by renotubular epithelia of mouse embryo 
[4]. In healthy adult rodents, PGRN continues to be 
expressed in the kidney, strongly in the transitional epi-
thelium of the ureter; but weakly in the proximal and dis-
tal convoluted tubules of the cortex and collecting ducts 
of the medulla [5]. In humans, the PGRN expression in 
kidneys remains unknown.
The first evidence of the protein was found during 
guinea pig spermatogenesis, when an acrosomal gly-
coprotein, named acrogranin, was detected [6]; and 
later identified as the guinea pig equivalent of PGRN 
[7]. PGRN has growth factor–like properties, being 
involved in early embryogenesis [4], wound repair and 
tissue remodeling [8]. It regulates cell division, survival, 
and migration, mainly via extracellular regulated kinase 
(ERK) and phosphatidylinositol 3-kinase (PI3K) pathways 
[8]. The growth factor–like properties of PGRN could be 
involved in physiology of tissue repair or in diseases such 
as cancer [1]. By the same pathways (ERK and PI3K), 
PGRN contributes to tumor proliferation, invasion and 
cell survival [9–11]. This molecule has previously been 
linked to many cancer types, as breast [12], ovarian [13], 
cervical [14], gastrointestinal [15] and kidney cancers 
[16].
Progranulin is secreted in an intact form and can be 
cleaved into granulins by proteases [2, 3]. Granulins are 
small proteins of approximately 6  kDa characterized by 
a conserved motif of 12 cysteines and play a role in the 
extracellular regulation of cell function and growth [8]. It 
has been suggested that the full length form of the pro-
tein (PGRN) has anti-inflammatory action, while released 
granulins have the opposite effect, increasing the pro-
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[1]. The intact PGRN is reported bind to tumor necrosis 
factor receptor (TNFR), inhibiting the binding of tumor 
necrosis factor-α (TNFα) and its proinflammatory signal-
ing [17, 18]. In mouse models of arthritis, PGRN prevents 
inflammation [17]. In humans, increased serum levels of 
PGRN are observed in rheumatoid arthritis, but its rela-
tion to the pathogenesis of the disease remains unclear 
[19]. Elevated PGRN levels are observed in the skin of 
psoriasis patients [20, 21], mice dermatitis model [20, 
21] and wounds [1]. Some authors suggest that PGRN 
has the effect of attenuating inflammation in these condi-
tions, acting as an anti-inflammatory molecule [20, 21].
In central nervous system, PGRN has neurotrophic and 
neuroprotective actions [22]. It is involved in neurite out-
growth and possibly plays a role in plasticity and remod-
eling in the adult brain [23]. In addition, PGRN protects 
neurons from premature death [8] and acts in the response 
to stress [23] and neuroinflammation [22]. PGRN defi-
ciency is associated with neurodegeneration and fronto-
temporal dementia (FTD), mainly due to mutation in GRN 
[24]. However, PGRN expression is upregulated in micro-
glia in neurodegenerative disease [25] as FTD, especially in 
brain areas with a substantial pathology [26]. It is unclear if 
it represents a result of microglia response to injury or an 
active contribution to the disease progression [22].
After acute ischemia–reperfusion injury, lower PGRN 
levels are observed in mice brain [27] and kidney [28]; 
and treatment with recombinant PGRN could attenuate 
inflammation in this condition [27, 28]. PGRN also seems 
to protect against acute focal cerebral ischemia in rats by 
attenuation of blood–brain barrier disruption, neuroin-
flammation suppression, and neuroprotection [29].
Despite the reported anti-inflammatory properties of 
PGRN in some conditions, it seems to be a more com-
plex molecule, revealing an opposite metabolic function. 
In the periphery, the intact form of PGRN has been asso-
ciated with proinflammatory effects, since PGRN was 
recently recognized as an adipokine related to obesity 
and insulin resistance [3, 30]. Nothing further is known 
about the relationship of PGRN with its proteolytic gran-
ulins in obesity and insulin resistance.
Review
Adipose tissue, obesity and PGRN
Since the discovery of leptin in 1994, adipose tissue has 
been recognized as an endocrine organ, with its secreted 
adipokines playing many functions in the body [31]. Lep-
tin acts on energy metabolism, regulating appetite and 
food intake, as an anorexigenic hormone [32]. In obe-
sity, its levels are increased; however, leptin resistance 
is observed, impairing leptin functions [33]. A similar 
biological process is suggested for PGRN [34]. There is 
evidence that the administration of PGRN in the mice 
hypothalamus significantly suppresses fasting-induced 
feeding and body weight gain in a dose-dependent man-
ner, possibly through hypothalamic neuropeptide Y and 
the melanocortin system [34]. However, in obesity, a 
resistance to the anorexigenic effects of PGRN may con-
tribute to increased food intake [34].
In obesity, PGRN levels are increased [30, 35, 36]. 
Both experimental studies [35] and those performed in 
humans [30, 36] have reported the relationship between 
PGRN and adiposity. In ob/ob mice, a well-characterized 
obese and insulin resistance model, there are elevated 
PGRN serum levels and upregulation of Grn in white 
adipose tissue [35]. In humans, previous studies report a 
positive correlation between body mass index (BMI) and 
PGRN serum levels [30, 36, 37].
Progranulin is positively correlated to body fat percent-
age and waist circumference [36–38]. Fat distribution is 
related to PGRN levels, revealing higher PGRN serum 
concentration in subjects with visceral obesity [36]. It is 
known that visceral fat and its secreted adipokines and 
immune cell-derived cytokines are involved in chronic 
inflammation [31]. PGRN seems to play a role on this 
process, due its chemotactic activity, recruiting mono-
cytes into adipose tissue as well as monocyte chemoat-
tractant protein-1 (MCP-1) [36]. Furthermore, there is 
evidence that Grn deficient mice had significantly less 
infiltration of macrophages in adipose tissue [35]. Taken 
together, these findings suggest a proinflammatory effect 
of PGRN. This is supported by human studies that found 
a positive correlation between PGRN and C-reactive pro-
tein (CRP) [36, 39] and interleukin 6 (IL-6) [30, 39].
The effects of PGRN in obesity and inflammation have 
also revealed its influence on insulin resistance. A posi-
tive correlation between PGRN levels and HOMA-IR 
index (Homeostasis Model Assessment for insulin resist-
ance) has been reported [30, 37]. In morbid obesity, 
patients with insulin resistance have elevated PGRN 
serum concentration [40].
Experimental studies reported that PGRN pro-
motes IL-6 expression in adipose cells, and its eleva-
tion enhances cytokine signaling-3 (SOCS3) expression 
via activation of JAK-STAT signaling. This mechanism 
can inhibit tyrosine phosphorylation of insulin receptor 
substrate-1 (IRS-1), leading to insulin resistance [35]. 
Additional evidence reports that Grn deficient mice fed 
with high fat diet presented improved insulin sensitivity. 
Moreover, body weight, fat mass and size of adipocytes 
were lower in Grn deficient mice compared to the wild-
type mice receiving a standard diet [35]. These findings 
suggest a relevant association of PGRN with obesity and 
insulin resistance [35], as summarized in Fig. 1.
Recently, experimental studies reported that PGRN 
increases autophagic activity and triggers endoplasmatic 
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reticulum (ER) stress in cultured human adipocytes, 
impacting on insulin signaling [37]. First, in multiple 
insulin-resistant cellular models there were increased lev-
els of PGRN and autophagic imbalance. In PGRN defi-
cient adipocytes, decreased markers of autophagy were 
observed. Moreover, adipocytes treated with PGRN and 
then stimulated with insulin revealed diminished IRS-1 
and Akt phosphorylation and increased autophagic dis-
order. Mechanisms suggested involve ERK and mam-
malian target of rapamycin (mTOR) pathways [37]. ERK 
activation impairs IRS-1 activity and is associated with 
autophagy and ER stress-induced insulin resistance [41]. 
Likewise, inhibition of mTOR reduces insulin action and 
promotes autophagic disorders in adipocytes [42]. Pos-
sibly, PGRN effects are mediated by ERK activation and 
impaired mTOR phosphorylation [37] (Fig. 1). Moreover, 
there is evidence that PGRN could exert a causative role 
in hepatic insulin resistance, as observed in mice treated 
with PGRN for 21 days. Animals presented impaired glu-
cose and insulin tolerance, and hepatic autophagy imbal-
ance [43].
Regulation of PGRN on autophagy disorders and insu-
lin resistance seems to be partially mediated through 
TNFR-1 via NF-kB signaling [37, 43]. Previous stud-
ies revealed that PGRN binds to TNFR, impairing 
the TNFα/TNFR interaction and suppressing chronic 
inflammation in mouse models of arthritis [17]. Although 
one study failed to demonstrate the binding of PGRN to 
TNFR [44], a recent publication reinforces this interac-
tion [45]. Further evidence is required to elucidate the 
effects of PGRN binding to TNFR in different tissues, but 
it is possible that PGRN has dual roles in inflammation, 
exhibiting pro- and anti-inflammatory proprieties.
Some authors suggest that PGRN could be involved 
in the growth of adipose tissue [3]. It is known that the 
expansion of fat mass during obesity is followed by angi-
ogenesis [46]; and PGRN has previously been linked to 
vessel formation [47]. Therefore, this adipokine could 
also contribute to increase adiposity (Fig.  1). However, 
this hypotheses needs to be confirmed by further studies.
Regarding adipogenesis, the role of PGRN is not fully 
understood. Its anti-adipogenic effects were reported in 
a previous study using porcine preadipocytes [48]. PGRN 
promoted ERK activation that phosphorylate peroxisome 
proliferator-activated receptor-gamma (PPARg) at the 
serine 112 site, impairing its function on adipocyte dif-
ferentiation [48]. The effect of PGRN on ER stress also 
suppressed adipogenesis in cultured human adipose cells 
[37]. Moreover, Matsubara et  al. [35] found that PGRN 
expression decreased with differentiation of 3T3-L1 adi-
pose cells assessed by pre-adipocyte factor-1, PPARg, and 
fatty acid binding protein. On the other hand, a positive 
significant correlation between circulating PPARg and 
PGRN was observed in obese subjects [49].
Fig. 1 Association of PGRN with obesity, insulin resistance and type 2 diabetes mellitus. PGRN progranulin, IL-6 interleukin-6, TNFR tumor necrosis 
factor receptor, mTOR mammalian target of rapamycin, ERK extracellular regulated kinase, IRS-1 insulin receptor substrate-1, SOCS3 cytokine signal-
ing-3, T2DM type 2 diabetes mellitus
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Type 2 diabetes mellitus and PGRN
From 1988 to 2010, the total number of persons with dia-
betes increased by almost 75 % [50]. In 2012, there were 
an estimated 371 million adults living with diabetes, with 
4.8 million deaths attributable to this disease [51].
Type 2 diabetes mellitus (T2DM) is characterized by a 
resistance to insulin action and inadequate compensatory 
insulin secretory response, leading to hyperglycemia [52]. 
Obesity and visceral fat are probably the main risk factors 
for T2DM [53] and are involved in its pathophysiology as 
well as inflammation and insulin resistance [31]. Genetic 
and T2DM family history are widely studied and several 
genes have been associated with T2DM development [54, 
55].
The PGRN gene is located in the chromosome region 
17q21.32. The long arm of chromosome 17 was previ-
ously linked to visceral adipose tissue, waist circum-
ference and BMI in Hispanic families in the Insulin 
Resistance Atherosclerosis Family Study [56]. Moreover, 
linkage signals of fasting glucose was found with 17q in 
young European sib-pairs, suggesting an association with 
T2DM [57]. Other important genes are located in this 
chromosome region, as SOCS3 [58] and genes involved 
in food intake [59].
Recently, new markers have been studied in the patho-
genesis of diabetes, involving many adipokines [60, 61], 
such as PGRN [30, 36, 38]. There is evidence that PGRN 
levels are increased in T2DM when compared to non-
diabetic subjects [30, 36, 38, 62]. PGRN is closely related 
to glucose metabolism. There is a positive correlation 
between PGRN and A1C, fasting plasma glucose and 
2 h post-challenge plasma glucose [30, 36, 37]. Elevated 
PGRN concentrations are also observed in impaired glu-
cose tolerance subjects, revealing its role in prediabetic 
states [38]. Moreover, a recent study evaluating T2DM 
patients reports that obese subjects present higher levels 
of PGRN [30].
The association of PGRN with T2DM is mainly 
explained by its role in adipose tissue and insulin resist-
ance. PGRN promotes IL-6 expression, impairing insulin 
signaling [35]. Moreover, it is a chemoattractant protein 
that recruits monocytes into adipose tissue, promoting 
inflammatory response with increased cytokines levels 
[36] (Fig. 1).
Decrease in circulating PGRN levels can be obtained 
with long term diet intervention [63] and exercise train-
ing [36]. A recent study evaluated the change in PGRN 
levels after 24  months of dietary intervention, and 
showed that the decrease was sustained throughout this 
period, irrespective of weight stabilization or partial 
weight regain [63]. Another study identified a signifi-
cantly decrease of ~20 % in PGRN serum concentration 
after a 4-week training program, only in T2DM patients 
[36].
Other metabolic disorders associated with T2DM 
have also been linked to PGRN. A positive correlation 
observed between total cholesterol [36], triglycerides [30, 
37] and PGRN suggests a role in dyslipidemia. Patients 
with metabolic syndrome present higher serum PGRN 
concentration [37, 64] and the number of metabolic syn-
drome components have a significant positive correlation 
with PGRN levels [39]. Elevation of PGRN expression in 
omental adipose tissue is also observed in patients with 
metabolic syndrome, indicating a potential contribu-
tion of adiposity to increased PGRN serum levels [37]. 
Moreover, patients with metabolic syndrome also present 
increased autophagic activity and ER stress in adipose 
tissue [37]. Finally, the effects of PGRN in obesity, insulin 
resistance and inflammation contribute to its association 
with atherosclerosis [39].
T2DM is associated with poor outcomes, character-
ized by macro and microvascular complications. Inten-
sity and duration of hyperglycemia exposure leads to 
vascular and nervous damage, resulting in organ dys-
function, such as kidney, eyes, nerves, heart and blood 
vessels [52, 65].
Kidney disease and PGRN
Chronic kidney disease (CKD) is defined as a reduced 
glomerular filtration rate (GFR), increased urinary 
albumin excretion (UAE), or both. The incidence and 
prevalence of CKD differ substantially across countries; 
however, the estimated worldwide prevalence is around 
8–16 % [66].
Although hypertension, glomerulonephritis and other 
comorbidities can lead to development of renal dysfunc-
tion, diabetes is the main cause of CKD [66]. In Brazil, 
it is the primary kidney disease in most patients starting 
dialysis [67]. The prevalence of diabetic kidney disease 
(DKD) increases over the years after the T2DM diagno-
sis, affecting about 25 % of patients with 10 years of the 
pathology [68]. Hyperglycemia associated with hyperten-
sion can lead to glomerulus injury [69, 70]. Tissue inflam-
mation promotes kidney fibrosis, leading to protein 
clearance, such as albuminuria [71]. Although increased 
UAE are common in DKD, some patients with T2DM 
present reduced GFR, even in the absence of albuminuria 
[69, 70, 72].
Chronic kidney disease complications include 
increased all-cause and cardiovascular mortality, kidney-
disease progression, acute kidney injury, anaemia, min-
eral and bone disorders, fractures and cognitive decline 
[66]. When associated with diabetes, an increased risk of 
mortality is observed [67, 73].
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Recently, PGRN was described as an adipokine 
dependent of renal function [74]. Five hundred thirty-
two patients with stages 1–5 of CKD (according to the 
National Kidney Foundation classification) had their 
PGRN serum levels evaluated. Even after adjustment 
for age, sex and BMI, PGRN remained significantly dif-
ferent between the five subgroups of CKD, being higher 
in stage 5. Moreover, estimated GFR was identified as an 
independent predictor of PGRN circulating levels. These 
findings suggest that renal filtration is an important route 
of PGRN elimination [74]. However, the authors did not 
find a significant correlation between serum and uri-
nary PGRN in a subgroup of 145 patients, which limits 
their conclusions. There is also an hypothesis that PGRN 
might contribute to the proinflammatory state frequently 
observed in renal disease [74].
Progranulin also seems to be involved in DKD. In a 
recent study evaluating eighty-four T2DM patients, 
increased PGRN serum levels were described in mac-
roalbuminuric subjects [75]. The study also evaluated 
the presence of proliferative diabetic retinopathy and 
observed higher levels of PGRN in this group of patients, 
suggesting PGRN as a marker for diabetic microangiopa-
thy and its severity [75].
The association of urinary PGRN levels and renal dam-
age was investigated in seventy-four patients with type 1 
diabetes mellitus (T1DM) [76]. Subjects were evaluated 
at baseline, when urine was collected, and after 6 years, 
when albuminuria and early renal function decline 
(ERFD, defined as a decline in cystatin C-based estimated 
GFR of ≥3.3  % per year) were assessed. Patients with 
both ERFD and albuminuria presented higher urinary 
PGRN levels at baseline than patients who maintained 
normal renal function and normoalbuminuria, when 
adjusted by age, diabetes duration, baseline albumin 
excretion rate, HbA1C, cystatin C and uric acid. More-
over, PGRN was significantly predictive of ERFD and 
albuminuria in patients with type 1 diabetes in multivari-
able logistic regression [76]. The study also investigated 
urinary levels of Tamms–Horsfall glycoprotein, clusterin 
and human α-1 acid glycoprotein; and concludes that a 
panel of these three proteins plus PGRN could be used to 
predict early signs of DKD [76]. Table 1 summarizes pre-
sent data regarding PGRN and renal function.
There is little evidence regarding the association of 
PGRN and DKD in T2DM patients. The proinflamma-
tory effects of this adipokine could be involved in the 
pathway of renal damage, decreasing GFR and increasing 
albuminuria. When CKD is established, PGRN clearance 
is reduced and its effects could be potentiated. However, 
further studies are needed to elucidate this hypothesis.
In an acute condition, such as renal ischemia–rep-
erfusion injury, an experimental study observed lower 
levels of PGRN in the mice kidney [28]. Moreover, Grn 
deficient mice presented a higher elevation of serum 
creatinine and blood urea nitrogen, more severe mor-
phological injury and higher inflammatory response. 
Administration of recombinant PGRN in  vitro could 
Table 1 Studies characteristics regarding PGRN and renal function
CKD chronic kidney disease, T1DM type 1 diabetes mellitus, PGRN progranulin, ERFD early renal function decline, eGFR estimated glomerular filtration rate, MA micro- 
or macroalbuminuria, DKD diabetic kidney disease
Characteristic/
reference
Xu et al. [75] Richter et al. [74] Schlatzer et al. [76]
Patients 84 patients with T2DM and 12 health 
persons
532 patients with stages 1–5 of CKD 74 patients with T1DM
PGRN material Serum Serum Urine
Design Cross-sectional study Cross-sectional study Longitudinal study
Baseline: urine collection, PGRN dosage
3 and 6-year visit: assessment of MA and ERFD
Results regarding 
PGRN
PGRN serum levels are increased in 
T2DM patients with macroalbu-
minuria
Positive correlation between serum 
PGRN and urinary albumin excre-
tion rate
Negative correlation between PGRN 
and eGFR
PGRN serum levels are different between 
groups of CKD stages
↑ PGRN levels at stage 5 of CKD
CKD stage or eGFR are independently 
associated with PGRN serum levels
Lowest PGRN levels in patients who maintained 
normal renal function and normoalbuminuria 
(n = 35)
Nonsignificant increase in patients with either 
ERFD (n = 15) or MA (n = 16)
Significant increase in patients with both ERFD 
and MA (n = 8)
Urinary PGRN was significantly predictive of 
ERFD and MA in patients with T1DM
Conclusion PGRN might be considered as a 
marker for diabetic microangiopa-
thy and its severity
Renal function assessed as eGFR is a 
strong, independent predictor of 
serum PGRN
PGRN serum levels significantly increase 
with deteriorating renal function 
assessed as CKD stage
A panel of 4 proteins (PGRN, Tamms-Horsfall 
glycoprotein, clusterin and human α-1 acid 
glycoprotein) could be used to predict early 
signs of DKD
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attenuate inflammation after renal ischemia–reperfusion 
injury at least in part associated with a nucleotide-bind-
ing oligomerization domain containing 2 (NOD2)-medi-
ated immune response [28]. Therefore, PGRN plays a 
protective role and has an anti-inflammatory effect in the 
kidney after renal ischemia–reperfusion injury [28].
Conclusions
Progranulin is an emerging molecule which demands 
studies in different fields. Previous data have identified 
PGRN as a pro- and anti-inflammatory protein. Possibly, it 
plays distinct functions in different tissues/cells and meta-
bolic conditions, as reported in Table 2. It was previously 
demonstrated that expression of PGRN in intact skin is 
low, but in injured skin, it raises significantly [1]. In addi-
tion, PGRN exerts anorexigenic effect in lean state, but a 
resistance is observed in obesity, leading to increased food 
intake [34]. Moreover, in acute condition of ischemia–rep-
erfusion injury, PGRN plays an anti-inflammatory effect 
[27–29], while in obesity (a chronic condition), it is associ-
ated with insulin resistance and inflammation [35].
It is not fully understood if PGRN is a cause or conse-
quence of some conditions. PGRN could be involved in 
the pathogenesis of obesity and T2DM, and become a 
target for metabolic disorders prevention or treatment. 
In renal disease, it is not known if it could contribute to 
kidney damage or if it is only a route of PGRN elimina-
tion. In the last case, PGRN could be used as a marker of 
renal disease. Further studies are necessary to elucidate 
these questions and investigate the crosstalk between 
pro- and anti-inflammatory PGRN proprieties in differ-
ent tissues and conditions, in order to clarify the action 
mechanisms of this potential molecule.
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